Decreased renal 11-beta dehydrogenase type 2 (11β-HSD2) activity, as reflected by an increased urinary free cortisol to cortisone ratio (UFF/ UFE), is associated with having hypertension (HTN). The current study was conducted to determine if reduced 11β-HSD2 activity is also associated with having resistant HTN.
Original article
Cortisol and aldosterone are both secreted by the adrenal cortex and bind with similar affinity to the mineralocorticoid receptor (MR) in vitro. 1 Circulating concentrations of cortisol in vivo are 100-1000 fold higher than aldosterone. MR selectively binds to aldosterone due to the inactivation of cortisol to cortisone by 11-beta hydroxysteroid dehydrogenase type 2 (11β-HSD2). 2 Therefore, aldosterone is the major MR agonist. 11β-HSD2 is expressed in distinct MR rich tissues, specifically in sodium transporting epithelia such as distal nephron, colon, salivary glands, and in the placenta. 11β-HSD2 in the kidneys is primarily in the cortical collecting duct and has a protective role as it prevents cortisol activation of the MR. [2] [3] [4] [5] Apparent mineralocorticoid excess, is a rare form of saltdependent hypertension (HTN) 6 that is caused by 11β-HSD2 mutation resulting in MR activation by cortisol leading to sodium retention, hypokalemia, and HTN. The diagnosis of apparent mineralocorticoid excess is based on urinary cortisol metabolites with high ratio of urinary cortisol (UFF) to cortisone (UFE). 2, 5 Interestingly, normotensive healthy individuals may develop HTN with elevation of UFF/UFE through pharmacologic inhibition of the 11β-HSD2 activity with licorice or carbenoxolone. [7] [8] [9] [10] [11] Inactivating mutations and competitive inhibition of 11β-HSD2 cause inherited or acquired HTN, leading to a state of excess MR activation in the kidneys that is characterized by an elevated UFF/UFE. These observations have lead to a growing interest in the role of 11β-HSD2 as a cause of HTN. In patients with primary HTN the half-life of cortisol is prolonged and UFF/UFE metabolites have been shown to be increased. These findings suggest that 11β-HSD2 may be mutated or inhibited in these patients. 2, 5 Some studies have observed that UFF/UFE ratios were significantly greater in primary hypertensive patients when compared to normotensive individuals; however, UFF/UFE values vary greatly in primary hypertensive patients (0.8 ± 0.04 12 to 8.6 ± 4.75 13 ). A UFF/UFE, if ≥3, corresponds to 50% reduction in 11β-HSD2 activity and is though to contribute to blood pressure (BP) elevation. Data regarding a higher than normal ratio (≥1) but <3 has been inconsistent. 14 Whether 11-Beta Dehydrogenase Type 2 Activity Is Not Reduced in Treatment Resistant Hypertension alterations in 11β-HSD2 activity contributes to BP remains under discussion. [15] [16] [17] Resistant HTN defined as a lack of BP control despite using 3 or more antihypertensive medications, including a diuretic, is present in 10-20% of the hypertensive population. 18, 19 We hypothesized that reduced 11β-HSD2 activity as reflected by an increase in UFF/UFE might contribute to the development of RHTN. The aim of this study was to determine if reduced 11β-HSD2 activity is associated with having RHTN.
METHODS
The study is a retrospective analysis of consecutive patients referred to the University of Alabama at Birmingham Hypertension Clinic for evaluation and treatment of RHTN between 2012 and 2014.
Study population
The analysis included 55 patients with RHTN defined as having clinic BP ≥140/90 mm Hg despite use of a ≥3 drug regimen, including a diuretic 17 and 38 patients with controlled, non-RHTN (control group), defined as having BP <140/90 and on ≤3 medications. The majority of RHTN patients were on a 4-drug treatment regimen including chlorthalidone, an angiotensin converting enzyme inhibitor or angiotensin receptor blocker, a calcium channel blocker, and a beta blocker. All patients had been on stable BP antihypertensive regimen for at least 4 weeks prior to biochemical evaluation.
Baseline parameters
Assessed variables included demographics and anthropometrics (age, gender, body mass index-BMI), number of antihypertensive medications, duration of HTN, and biochemical analysis (serum potassium, creatinine, serum aldosterone concentration (SAC-ng/dl), plasma renin activity (PRA-ng/ml/h), aldosterone-renin ratio, and 24-hour urinary aldosterone (U-Aldo, µg/24 h), sodium (U-Na + , mEq/24 h), potassium (U-K + , mEq/24 h), cortisol (UFF, µg/24 h), cortisone (UFE, µg/24 h), UFF/UFE ratio, and urinary creatinine(mg/24 h). UFF and UFE levels were obtained by gas chromatography and mass spectrometry using a stable isotope-labeled internal standard. 20 Aldosterone-renin ratio was calculated by the formula aldosterone-renin ratio = SAC/PRA. SAC, PRA, and 24-hour urine levels were analyzed by mass spectrometry at Mayo Clinic (Mayo Medical Laboratories, Rochester, MN). [21] [22] [23] [24] Adequacy of the 24-hour urine collection was assessed by measuring 24-hour U-Cr by comparing total creatinine in the sample to predicted creatinine. 25 As per routine clinical care, 24-hour urine collections were done while patients were consuming their usual diet and without change in their level of physical . 18 Patients were advised to return the collections early in the morning. Adherence was measured by patient self-report and by monitoring of medication refill rates.
BP assessment
Clinic BP was measured according to guidelines by a trained physician using the auscultatory method with a manual sphygmomanometer (Welch Allyn, Skaneateles Falls, NY). Patients were seated for 5 minutes in a rested position with both feet on the ground and with their back supported while the arm was supported at the level of the heart. An appropriate sized cuff was used with a cuff bladder encircling at least 80% of the arm. Three BP readings were taken at intervals of 2 minutes by the physician and the second and third reading was used to average BP. The BP was measured in both arms and the arm with the higher BP was used for further BP measurements. 18 
Exclusion criteria
Exclusion criteria for this analysis included: missing baseline demographics, suspicion of being nonadherent with prescribed medications, documented chronic kidney disease, treated with antidepressants, thyroid replacement hormones, or mineralocorticoid antagonist (spironolactone or eplerenone), diagnosed with primary aldosteronism (defined as PRA <1 ng/ml/hr and 24-hour U-Aldo >12 µg).
The study was approved by the University of Alabama at Birmingham Institutional Review Board and conducted according to institutional guidelines.
Statistical analysis
Demographics and clinical characteristics were summarized using descriptive statistics with mean ± SD 10 for continuous variables, frequency, and percentage for categorical variables. A chi-squared test and Student's t-test were performed to make the statistical comparisons of demographics, clinical, and laboratory measures between uncontrolled RHTN and non-RHTN groups. The reference ranges from University of Alabama at Birmingham and Mayo Clinic were also used for comparisons of laboratory measures and 24-hour urinary analysis. As an exploratory analysis, the associations of UFF/UFE ratio to select patients' characteristics were evaluated using the Student's t-test and linear regression. A P value of <0.05 was considered statistically significant in 2-tailed statistical tests. All analyses were conducted using SAS 9.4 software (SAS Institute, Cary, NC). The box and whisker plot was created using R 3.3.0.
RESULTS
There were no significant differences in age, gender, race, BMI, duration of HTN, in patients with uncontrolled RHTN vs. with non-RHTN ( Table 1) . The entire cohort, both study groups combined, were on average 56 years old, with slightly more woman and more Caucasians, and mostly obese with BMI ≥30 kg/m 2 . By definition, systolic BP, diastolic BP, and number of antihypertensive medications were significantly higher in patients with uncontrolled RHTN versus non-RHTN (167.5 ± 28.2/91.2 ± 18.8 mm Hg vs. 126.6 ± 11.4/77.8 ± 8.65 mm Hg and 4.31 ± 1.23 vs. 2.74 ± 0.6, respectively).
Biochemical analysis revealed no significant abnormalities in serum potassium, serum creatinine or SAC, and a nonsuppressed PRA in wither study group. The aldosterone-renin ratio was significantly higher in the uncontrolled RHTN group. (Table 2 ) All 24-hour urine collections were adequate. Mean U-Na + was 176.1 ± 91.4 mEq/24 h for RHTN patients compared to 175.5 ± 96.8 mEq/24 h (P = 0.97) in the non-RHTN group. Overall, 36.4% (20/55) of the patients with RHTN and 33.3% of the non-RHTN patients (6/18) had U-Na + >200 mEq/24 h indicative of high sodium intake. Mean UFF and UFE were within normal limits in both groups, with nonsignificant higher trends observed in the control subjects. 26 The activity of 11β-HSD2 estimated by UFF/UFE showed that both uncontrolled RHTN and non-RHTN patients had a low ratio, i.e., <1.5 (0.22 ± 0.16, and 0.19 ± 0.1 [P = 0.36], respectively), indicating normal enzyme activity. The distribution of UFF/UFE was similar in both groups, with the ratio ranging between 0.06-0.59 for RHTN and 0.067-0.44 in control (Figure 1 ). There was no significant association between UFF/UFE ratio and age, gender, race, BMI, U-Aldo, presence of primary aldosteronism, or U-Na + levels.
DISSCUSSION
11β-HSD2 activity, as indexed by UFF/UFE ratio is not different in patients with uncontrolled RHTN vs. patients with controlled, non-RHTN. We observed a mean UFF/UFE of 0.22 in patients with RHTN and 0.19 in patients without RHTN, indicating normal conversion of cortisol to cortisone in both study groups. To our knowledge this is the first study to assess 11β-HSD2 activity in RHTN. The findings are consistent with normal enzyme activity in this population suggesting that RHTN is not attributable to variation in conversion of cortisol to cortisone.
The role of 11β-HSD2 activity in the development of HTN has been evaluated in several studies comparing normotensive patients to patients with primary HTN (Table 3 ). In around 20% of patients with primary HTN with no overt symptoms of apparent mineralocorticoid excess, a mild defect in 11β-HSD2 activity is found. 27, 28 Previous studies assessed 11β-HSD2 activity by measuring conjugated urinary steroids metabolites tetrahydrocortisol/tetrahydrocortisone (THF/THE). However, these measurements have low sensitivity, especially if 11β-HSD activity elsewhere in the body is abnormal. UFF/UFE is therefore thought to provide the most sensitive index of 11β-HSD2 activity. 2, 5, [29] [30] [31] [32] We assessed 11β-HSD2 activity by UFF/UFE, finding a mean of 0.22 ± 0.16 in RHTN group and 0.19 ± 0.09 in non-RHTN patients, indicating enzyme activity capable of converting cortisol to cortisone at a normal rate. We did not find any association between any biochemical laboratory parameters and UFF/UFE levels. A recent study by Mariniello et al. of White Italian patients compared UFF/UFE in 292 patients with primary HTN vs. 163 normotensive controls to assess whether variants of 11β-HSD2 might be associated with the development of HTN. 12 There were significant differences in both groups-hypertensive patients were younger (47 vs. 57 years), had a higher mean BMI (27 vs. 25 kg/m 2 ). However, UFF/ UFE was significantly higher in the hypertensive population than normotensives, 0.80 ± 0.04 vs. 0.57 ± 0.03, respectively (P < 0.01). The investigators concluded that the increase in UFF/UFE, a sensitive marker for renal 11β-HSD2 activity, in patients with HTN might be due to genetic alterations consistent with the growing evidence that mutations or polymorphisms of this enzyme may play a role in causing HTN. 14, 30, 33, 34 The data also showed that the UFF/UFE ratio was significantly higher in salt-sensitive patients (0.9 ± 0.05) compared to salt-resistant patients (0.65 ± 0.05), reflecting reduced 11β-HSD2 activity. UFF and UFE mean values in this study were not reported. Our cohort included participants older than the primary HTN group in Mariniello's cohort and more obese individuals. The mean UFF/UFE in both RHTN patients and in the control group were lower than the ratios found by Mariniello et al. Note that, African Americans tend to be more salt-sensitive than Caucasians, such that and one would expect a difference in the ratio when analyzing RHTN cohort. 35 However, in the current study, the UFF/UFE was similar in African Americans and Caucasians indicating normal 11β-HSD2 activity.
Campino et al. estimated activity of 11β-HSD2 by UFF/ UFE and compared the enzyme activity in 102 patients with primary HTN to 18 normotensive individuals in a Chilean population. 36 Of the primary hypertensive population, 15.7% had a high UFF/UFE due to an increase in cortisol 37 In this study by Campino et al., U-Na + values were similar across all studied groups (141.0 in the hypertensive population vs. 141.5 mEq/l in the normotensives) and were not associated with UFF/UFE. Similarly, we did not find any effect of U-Na + on UFF/UFE in our cohort, although mean U-Na + levels were higher than levels observed by Campino et al.
Based on a study on children with primary HTN, Mongia et al. 13 hypothesized that a defect in renal cortisol metabolism, as indicated by THF/THE or UFF/UFE elevation, secondary to a decrease in 11β-HSD2 activity, stimulates MR through cortisol and leads to development of HTN. Study limitations included using spot urine a less accurate assessment of urine metabolites UFF and UFE than 24-hour urine collection. The population consisted mostly of African American children. UFF/UFE ratio was significantly higher in the patients with HTN (8.60 ± 4.75) compared to controls (3.66 ± 1.60, P < 0.005). They, however, did not use UFF/ UFE to index 11β-HSD2 activity and that may be due to the poor quality of measurement using spot urine. 38 Despite that, these study findings further supports the significance of 11β-HSD2 activity deficiency in the development of primary HTN. This was in contrast to our findings in which we did not observe any deficiency in enzyme activity in RHTN patients.
Not all studies have found higher UFF/UFE in primary HTN patients compared to normotensives. Kosicka et al. found no significant differences in UFF/UFE between hypertensives and controls. 39 However, the median of UFF/ UFE was higher in hypertensives (n = 79) than the controls (n = 70), but not significant. UFF/UFE exceeded the reference range, ≤0.6 in 15.9% of hypertensive subjects and 7.1% of normotensives. The patients with HTN were more obese with a mean BMI of 30.5 kg/m 2 and had a mean age of 44 years. UFF and UFE in the hypertensive group were significantly lower than normotensives, 18.5 µg/24 h vs. 28.5, P = 0.0002 and 58.9 vs. 79.4, P = 0.0015, respectively. This cohort has very similar baseline characteristics to the current cohort. Our results are in agreement with Kosicka et al. as we found no association between UFF/UFE ratio and RHTN. The mean UFF/UFE value of 0.22 observed by us in patients with RHTN was less than the cutoff used by Kosicka, i.e., 0.6. The values we observed in our study groups overlapped with the UFF/UFE range in both normotensive and primary hypertensive patients seen by Kosicka. Our findings, however, do not confirm those earlier observations. We observed a low ratio both in patients with RHTN and without RHTN, providing no evidence of alterations in 11β-HSD2 activity in either group.
Strengths of the current analysis include evaluation of a diverse cohort of patients with confirmed RHTN, comparison to a control group of patients without RHTN, and use of 24-hour urine values to index UFF/UFE. Limitations include the cross-sectional study design, having evaluated all patients during stable but ongoing antihypertensive treatment, having measured only 11β-HSD2 and not 11β-HSD type 1 activity, and having not confirmed medication adherence by measurement of serum or urinary drug levels.
In summary, 11β-HSD2 activity is not reduced in patients with RHTN suggesting that variation in the conversion of cortisol to cortisone does not contribute to development of antihypertensive treatment resistance. The negative findings provide important insight into the mechanisms of RHTN.
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